Clinical Trials Logo

Burkitt Lymphoma clinical trials

View clinical trials related to Burkitt Lymphoma.

Filter by:

NCT ID: NCT00183976 Terminated - Clinical trials for Non-Hodgkin's Lymphoma

Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas

Start date: April 2005
Phase: Phase 2
Study type: Interventional

This study is for patients who have been treated before and either the treatment did not work or the lymphoma has come back.

NCT ID: NCT00180895 Terminated - Burkitt Lymphoma Clinical Trials

Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL

Start date: June 2004
Phase: Phase 2
Study type: Interventional

This is a multicentric phase II study of Mabthera (rituximab) in children and adolescents with relapsed and refractory B-cell NHL/L3ALL. The primary objective is to determine the response rate of Rituximab as single agent in relapsed or refractory Burkitt lymphoma, L3 acute leukemia, large B-cell lymphoma and non subclassified aggressive B-cell NHL

NCT ID: NCT00126191 Terminated - Burkitt Lymphoma Clinical Trials

Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma

Start date: July 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to learn more about how well a chemotherapy regime including rituximab works in treating patients with Burkitt or atypical Burkitt lymphoma.

NCT ID: NCT00101244 Terminated - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma

Start date: November 2004
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of SB-715992 in treating patients with metastatic or unresectable solid tumors or Hodgkin's or non-Hodgkin's lymphoma. Drugs used in chemotherapy, such as SB-715992, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing

NCT ID: NCT00101205 Terminated - Clinical trials for Refractory Chronic Lymphocytic Leukemia

Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

Start date: November 2004
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of oxaliplatin and etoposide in treating young patients with recurrent or refractory solid tumors or lymphomas. Drugs used in chemotherapy, such as oxaliplatin and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Oxaliplatin may also help etoposide work better by making cancer cells more sensitive to the drug. Giving oxaliplatin together with etoposide may kill more cancer cells.

NCT ID: NCT00096005 Terminated - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

Start date: November 2004
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of giving tanespimycin together with bortezomib in treating patients with advanced solid tumors or lymphomas. (Accrual for lymphoma patients closed as of 11/27/09) Drugs used in chemotherapy, such as tanespimycin, work in different ways to stop cancer cells from dividing so they stop growing or die. Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. It may also increase the effectiveness of tanespimycin by making cancer cells more sensitive to the drug. Combining tanespimycin with bortezomib may kill more cancer cells.

NCT ID: NCT00089076 Terminated - Clinical trials for Recurrent Mantle Cell Lymphoma

MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma

Start date: June 2004
Phase: Phase 1/Phase 2
Study type: Interventional

Biological therapies, such as MDX-010, work in different ways to stimulate the immune system and stop cancer cells from growing. This phase I/II trial is studying the side effects and best dose of MDX-010 and to see how well it works in treating patients with recurrent or refractory B-cell non-Hodgkin's lymphoma.

NCT ID: NCT00060112 Terminated - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma

Start date: March 2003
Phase: Phase 1
Study type: Interventional

Drugs used in chemotherapy such as gemcitabine use different ways to stop cancer cells from dividing so they stop growing or die. Oblimersen may increase the effectiveness of gemcitabine by making cancer cells more sensitive to the drug. This phase I trial is studying the side effects and best dose of oblimersen and gemcitabine in treating patients with metastatic or unresectable solid tumors or lymphoma

NCT ID: NCT00058461 Terminated - Clinical trials for Recurrent Childhood Acute Lymphoblastic Leukemia

Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

Start date: November 2003
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well rituximab together with ifosfamide, carboplatin, and etoposide works in treating young patients with recurrent or refractory non-Hodgkin's lymphoma or acute lymphoblastic leukemia. Chemotherapy drugs, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining ifosfamide, carboplatin, and etoposide with rituximab may kill more cancer cells.

NCT ID: NCT00019708 Terminated - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Start date: June 1999
Phase: Phase 1
Study type: Interventional

Phase I trial to study the effectiveness of geldanamycin analogue in treating patients who have advanced solid tumors or non-Hodgkin's lymphoma. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die.